Study design of a phase ii clinical trial to assess the efficacy and safety of eperisone in japanese type 2 diabetes patients with risk and non-risk alleles of CDKAL1

Kourin Sakakida, Fan Yan Wei, Takafumi Senokuchi, Seiya Shimoda, Tatsuyuki Kakuma, Eiichi Araki, Kazuhito Tomizawa

Research output: Contribution to journalArticle

Abstract

Genetic variation in Cdk5 Regulatory Associated Protein 1-Like 1 (CDKAL1) is associated with the development of type 2 diabetes (T2D). Dysfunction of CDKAL1 impairs the translation of proinsulin, which leads to glucose intolerance. Eperisone, an antispasmodic agent, has been shown to ameliorate glucose intolerance in Cdkal1- deficient mice. We have launched a phase II clinical study to investigate the potential anti-diabetic effect of eperisone in T2D patients carrying risk or non-risk alleles of CDKAL1. The primary endpoint is the change of hemoglobin A1c (HbA1c) levels. We also examined whether the efficacy of eperisone in T2D patients is associated with CDKAL1 activity.

Original languageEnglish
Pages (from-to)423-426
Number of pages4
JournalActa Medica Okayama
Volume72
Issue number4
Publication statusPublished - Jan 1 2018
Externally publishedYes

Fingerprint

Medical problems
Type 2 Diabetes Mellitus
Alleles
Clinical Trials
Safety
Glucose Intolerance
Proteins
Glucose
Proinsulin
Parasympatholytics
Hemoglobins
eperisone

Keywords

  • Diabetes
  • Glucose
  • Insulin secretion
  • Single nucleotide polymorphism

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Study design of a phase ii clinical trial to assess the efficacy and safety of eperisone in japanese type 2 diabetes patients with risk and non-risk alleles of CDKAL1. / Sakakida, Kourin; Wei, Fan Yan; Senokuchi, Takafumi; Shimoda, Seiya; Kakuma, Tatsuyuki; Araki, Eiichi; Tomizawa, Kazuhito.

In: Acta Medica Okayama, Vol. 72, No. 4, 01.01.2018, p. 423-426.

Research output: Contribution to journalArticle

Sakakida, Kourin ; Wei, Fan Yan ; Senokuchi, Takafumi ; Shimoda, Seiya ; Kakuma, Tatsuyuki ; Araki, Eiichi ; Tomizawa, Kazuhito. / Study design of a phase ii clinical trial to assess the efficacy and safety of eperisone in japanese type 2 diabetes patients with risk and non-risk alleles of CDKAL1. In: Acta Medica Okayama. 2018 ; Vol. 72, No. 4. pp. 423-426.
@article{f95ba10798df439d98d82a8c49a1543b,
title = "Study design of a phase ii clinical trial to assess the efficacy and safety of eperisone in japanese type 2 diabetes patients with risk and non-risk alleles of CDKAL1",
abstract = "Genetic variation in Cdk5 Regulatory Associated Protein 1-Like 1 (CDKAL1) is associated with the development of type 2 diabetes (T2D). Dysfunction of CDKAL1 impairs the translation of proinsulin, which leads to glucose intolerance. Eperisone, an antispasmodic agent, has been shown to ameliorate glucose intolerance in Cdkal1- deficient mice. We have launched a phase II clinical study to investigate the potential anti-diabetic effect of eperisone in T2D patients carrying risk or non-risk alleles of CDKAL1. The primary endpoint is the change of hemoglobin A1c (HbA1c) levels. We also examined whether the efficacy of eperisone in T2D patients is associated with CDKAL1 activity.",
keywords = "Diabetes, Glucose, Insulin secretion, Single nucleotide polymorphism",
author = "Kourin Sakakida and Wei, {Fan Yan} and Takafumi Senokuchi and Seiya Shimoda and Tatsuyuki Kakuma and Eiichi Araki and Kazuhito Tomizawa",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "72",
pages = "423--426",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Study design of a phase ii clinical trial to assess the efficacy and safety of eperisone in japanese type 2 diabetes patients with risk and non-risk alleles of CDKAL1

AU - Sakakida, Kourin

AU - Wei, Fan Yan

AU - Senokuchi, Takafumi

AU - Shimoda, Seiya

AU - Kakuma, Tatsuyuki

AU - Araki, Eiichi

AU - Tomizawa, Kazuhito

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Genetic variation in Cdk5 Regulatory Associated Protein 1-Like 1 (CDKAL1) is associated with the development of type 2 diabetes (T2D). Dysfunction of CDKAL1 impairs the translation of proinsulin, which leads to glucose intolerance. Eperisone, an antispasmodic agent, has been shown to ameliorate glucose intolerance in Cdkal1- deficient mice. We have launched a phase II clinical study to investigate the potential anti-diabetic effect of eperisone in T2D patients carrying risk or non-risk alleles of CDKAL1. The primary endpoint is the change of hemoglobin A1c (HbA1c) levels. We also examined whether the efficacy of eperisone in T2D patients is associated with CDKAL1 activity.

AB - Genetic variation in Cdk5 Regulatory Associated Protein 1-Like 1 (CDKAL1) is associated with the development of type 2 diabetes (T2D). Dysfunction of CDKAL1 impairs the translation of proinsulin, which leads to glucose intolerance. Eperisone, an antispasmodic agent, has been shown to ameliorate glucose intolerance in Cdkal1- deficient mice. We have launched a phase II clinical study to investigate the potential anti-diabetic effect of eperisone in T2D patients carrying risk or non-risk alleles of CDKAL1. The primary endpoint is the change of hemoglobin A1c (HbA1c) levels. We also examined whether the efficacy of eperisone in T2D patients is associated with CDKAL1 activity.

KW - Diabetes

KW - Glucose

KW - Insulin secretion

KW - Single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=85051840298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051840298&partnerID=8YFLogxK

M3 - Article

C2 - 30140092

AN - SCOPUS:85051840298

VL - 72

SP - 423

EP - 426

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -